CIN-L02423MP1989PLC005438

To
Department of Corporate Services,
BSE Limited,
P J Tower, Dalal Street
Mumbai-400001

29 October 2022

Sir/ Madam,

Subject: Reconciliation of Share Capital Audit for Q.E. 30.09.2022- Submission of – Reg. Reference: Kabra Drugs Limited (524322).

With reference to above, we hereby enclose the Reconciliation of Share Capital Audit for quarter ended 30th September 2022 from Practicing Company Secretary.

This is for your information and record.

Thanking you,

Yours faithfully

For, KABRA DRUGS LIMITED

R. Muzh

DIRECTOR / AUTHORISED SIGNATORY



28.10.2022

To,

BSE LIMITED

Dear Sir,

Sub: Reconciliation of Share Capital Audit Report for the quarter ended 30th September 2022.

We are enclosing herewith the Reconciliation of Share Capital Audit report of M/s. KABRA DRUGS LIMITED for the quarter ended 30^{th} September 2022.

Thanking You,

Yours faithfully,

N. S. Pllyo

Narasimhan Srividhya Practicing Company Secretary



RECONCILIATION OF SHARE CAPITAL AUDIT REPORT

1 For Quarter Ended 30th September 2022

2 ISIN: INE23K01017

3 Face Value: Rs. 10/- per share

4 Name of the Company KABRA DRUGS LIMITED

5 Registered Office Address 270 Shastri Market Indore MP 452007 IN

6 Correspondence Address Same as above

Tel.No. 0731-2971305/6501305 7 Telephone & Fax Nos.

8 Email address kabradrugs@rediffmail.com

9 Names of the Stock Exchanges where the company's securities are listed

Bombay Stock Exchange Ltd.

10 Issued Capital

11 Listed Capital (Exchange-wise) (as per company's records)
Bombay Stock Exchange Ltd:

12 Held in dematerialized form in CDSL

13 Held in dematerialized form in NSDL

14 Physical

15 Total No. of shares (12+ 13+ 14)

Reasons for difference if any, between (10&11), (10&15),

Number of shares	% of Total Issued Capital	
43,88,600	100%	
11,86,440	27.04	
17,40,659	39.66	
14,61,501	33.30	
43,88,600	100.00%	



17 Certifying the details of changes in share capital during the quarter under consideration as per Table below:

Particulars	No.of Shares	Applied /Not Applied for listing	Listed on Stock Exchanges (specify Names)	Whether intimated to CDSL	Whether intimated to NSDL	In-prin. Appr. Pending for SE (specify Names)
	10000		Nil	== X	(55)	(5.7.

***Rights, Bonus, Preferential Issue, ESOPs, Amalgamation, Conversion, Buyback, Capital Reduction, Forfeiture, Any other (to specify).

18	Register of Members is Updated (Yes/No) If not, updated up to which date	YES Not Applicable
19	Reference of Previous Quarter with regards to excess dematerialized shares, if any	Nil
20	Has the company resolved the matter mentioned in Point No. 19 above in the current quarter? If not, reason why?	Not Applicable

Mention the total no. of requests, if any, confirmed after 21 days and the total no. of requests pending beyond 21 days with the reasons for delay:

Total No. of demat requests	No. of requests	No. of Shares	Reasons for delay
Confirmed after 21 Days	Nil	Nil	NA
Pending for more than 21 days	Nil	Nil	NA

Name, Telephone and Fax No. of the Compliance officer of the Co.

Ms. Monika Nishant
Membership Number:58835
Company Secretary

Ph: 022-28523437


Name, Address, Tel .& Fax No., Regn. No of the Auditor

NarasimhanSrividhya Company Secretaries in Practice-CP.No.14058 No.161-1Jayalakshmi Apartment, Lake view Road, West Mamabalam,Chennai - 33 e-mail id-srividhya0806@gmail.com Phone No.-9791712781

Appointment of common agency for share 24 registry work If yes (name & address)

M/s. Skyline Financial Services Pvt. Ltd. A/505, Dattani Plaza, Andheri Kurla Road, Safeed Pool, Mumbai- 400072.

Any other detail that the auditor may like to provide. (e.g.BIFR Company, delisting from SE, company changed its name etc.)



Date: 28.10.2022 Place: Chennai



Narasimhan Srividhya Practicing Company Secretary CP No.14058 UDIN:A034428D001392576 Peer Review Certificate No:829/2020 Unique Code:P2004TN081200

> NARASIMHAN SRIVIDHYA Company Secretary In Practice Mem. No : 34428 Cop : 14058